logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo UK Ltd.

Transparency

Daiichi Sankyo UK Ltd. collaborates with the Medical Community and Patient Organisations in order to implement programmes and activities that ultimately benefit patients, and the NHS. Funding associated with such collaborations can be (but is not restricted to)

  • Support to qualified recipients in the in the form of monies, or actual goods and services 
  • Donations to charitable causes, and patient organisations.
  • Fees and expenses paid to consultants for services such as chairing and speaking at company sponsored meetings, advisory boards etc
  • Sponsorship of Health Care Professionals to attend independent educational  third party meetings

These activities are governed by The Prescription Medicines Code of Practice Authority (PMCPA) which is a part of the Association of the British Pharmaceutical (ABPI) together with pharmaceutical industry laws and regulations laid down by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Bribery Act 2010.

Transparency and clarity are fundamental principles for successful collaboration. Daiichi Sankyo UK Ltd has therefore undertaken to make information publicly available, on the extent and nature of financial and non financial support, and transactions with its partners.

Grants and Donations
Grants and Donations 2012 

Grants and Donations 2013

Medical and Educational Goods and Services 2013
Medical and Educational Goods and Services 2013

Consultant Fees
Consultant Fees 2012 

Consultant Fees 2013

Consultant Fees 2014

Consultant Expenses

Consultant Expenses 2013

Consultant Expenses 2014

HCP Sponsorship
HCP Sponsorship 2012 

HCP Sponsorship 2013